Diligence memo · auto-generated · as of July 2, 2026
Abpro Corp
Abpro Corp looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Abpro Corp operates in Biotechnology, based in WOBURN.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Abpro Corp has raised $42M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $18M on 2020-01-15.
Most recent recorded round closed around 2022-03-30.
Valuation (modeled)modeled
Provath models Abpro Corp at approximately $38M (range $4.0M–$103M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.22× the median modeled value of Series B Biotechnology companies in 2022–2024 (197 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 24 months.
Last raise 4.3 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round was 9.0× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 80% of Biotechnology peers (4291 compared).
Modeled value ranks above 39% of those peers.
Closest niche peers: Mt McKinley Medical Holding Corp USA, YAP Therapeutics Inc, Pinteon Therapeutics, Inc., OncXerna Therapeutics, Ltd., EpiBiologics, Inc..
Peoplefiled
15 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.